Announcements
- Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
- Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
- Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
- Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
- Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
- Cara Therapeutics Reports Third Quarter 2023 Financial Results
- Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty
- Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
- Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
More ▼
Key statistics
As of last trade, Cara Therapeutics Inc (69C:FRA) traded at 0.631, 42.70% above the 52 week low of 0.4422 set on Feb 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.6005 |
---|---|
High | 0.631 |
Low | 0.6005 |
Bid | 0.6195 |
Offer | 0.68 |
Previous close | 0.6005 |
Average volume | 222.22 |
---|---|
Shares outstanding | 54.66m |
Free float | 46.68m |
P/E (TTM) | -- |
Market cap | 38.65m USD |
EPS (TTM) | -2.19 USD |
Data delayed at least 15 minutes, as of Apr 24 2024 14:52 BST.
More ▼